Current information in today's 10-Q UEEC posting.
Post# of 430
https://app.quotemedia.com/data/downloadFilin...2024-08-13
"In anticipation of receiving a Class III PMA (which cannot be assured), we are evaluating paths to rapidly grow our revenue and profits in all
potential market segments, with the objective of maximizing shareholder value. We do not intend to pursue the full commercialization of our products
independently nor to remain an independent company in the long term. Options under consideration include (i) a sale or merger of the Company with an industry leader in the wound care and surgical device sectors, which may include a pre-sale collaboration on commercialization and distribution and (ii)
one or more commercial partnerships with established market participants, without any specific, associated sale or merger transaction."
Page 18 alludes to product specifications identified by FDA!
$5-$10+
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)